Using biomarkers to personalize kidney disease treatment
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests if matching treatments to your specific kidney disease markers can better protect your kidneys. It looks at how well Finerenone, Dapagliflozin, and Semaglutide work alone or in a sequence.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a certain level of protein in your urine (UACR between 100 and 5000).
- You are already taking a stable dose of an ACE inhibitor or ARB medication for at least 4 weeks (or cannot take them).
- You have not had a heart attack, stroke, or other heart event in the last 12 weeks.
- You do not have type 1 diabetes, severe kidney disease (eGFR under 25), or certain other conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a urine test can help doctors choose the right medicines earlier to prevent kidney and heart problems in people with type 2 diabetes. You may join if you have type 2 diabetes but no severe heart failure.
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
This study tests a new medicine (BI 690517) combined with empagliflozin to see if it can help protect the heart and kidneys in people with chronic kidney disease. It may slow down kidney disease progression and reduce heart risks.
This study tests a personalized medication approach to lower kidney and heart risks in people with type 2 diabetes and early-to-moderate kidney disease. It may help you if you have a high chance of heart problems and can start new medications.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This trial tests whether combining dapagliflozin (a water-pill-like diabetes drug) with finerenone (a kidney-protective medication) works better than dapagliflozin alone for people with type 2 diabetes and kidney damage. Both drugs help reduce protein in urine and may slow kidney disease progression.
Hear when a new Chronic Kidney Disease(CKD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.